[go: up one dir, main page]

CU23584A1 - Composición farmacéutica que comprende la proteína nmb1796 - Google Patents

Composición farmacéutica que comprende la proteína nmb1796

Info

Publication number
CU23584A1
CU23584A1 CU20070151A CU20070151A CU23584A1 CU 23584 A1 CU23584 A1 CU 23584A1 CU 20070151 A CU20070151 A CU 20070151A CU 20070151 A CU20070151 A CU 20070151A CU 23584 A1 CU23584 A1 CU 23584A1
Authority
CU
Cuba
Prior art keywords
nmb1796
composition
protein
pharmaceutical composition
composition including
Prior art date
Application number
CU20070151A
Other languages
English (en)
Inventor
Feyt Rolando Pajon
Acosta Karem Cobas
Menendez Evelin Caballero
Diaz Darien Garcia
Garcia Gretel Sardinas
Blanco Sonia Gonzalez
Perez Olivia Niebla
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20070151A priority Critical patent/CU23584A1/es
Priority to EP08757901A priority patent/EP2168595A1/en
Priority to US12/664,278 priority patent/US20100172931A1/en
Priority to PCT/CU2008/000004 priority patent/WO2009000217A1/es
Priority to ARP080102713A priority patent/AR067151A1/es
Publication of CU23584A1 publication Critical patent/CU23584A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de una composición farmacéutica que comprende la proteína NMB1796. La composición de la presente invención confiere protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMB1796 se identificó como componente de las preparaciones de vesículas de membrana externa (VME) de Neisseria meningitidis, se obtuvo mediante la tecnología del ácido desoxirribonucleico (ADN) recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMB1796, la composición que la comprende posee alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. La composición de esta invención es aplicable en la medicina humana.
CU20070151A 2007-06-27 2007-06-27 Composición farmacéutica que comprende la proteína nmb1796 CU23584A1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CU20070151A CU23584A1 (es) 2007-06-27 2007-06-27 Composición farmacéutica que comprende la proteína nmb1796
EP08757901A EP2168595A1 (en) 2007-06-27 2008-06-16 Pharmaceutical compositions containing the protein nmb1796
US12/664,278 US20100172931A1 (en) 2007-06-27 2008-06-16 Pharmaceutical Composition Containing the NMB1796 Protein
PCT/CU2008/000004 WO2009000217A1 (es) 2007-06-27 2008-06-16 Composición farmacéutica que comprende la proteína nmb1796
ARP080102713A AR067151A1 (es) 2007-06-27 2008-06-24 Composicion farmaceutica que comprende la proteina nmb 1796

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070151A CU23584A1 (es) 2007-06-27 2007-06-27 Composición farmacéutica que comprende la proteína nmb1796

Publications (1)

Publication Number Publication Date
CU23584A1 true CU23584A1 (es) 2010-10-30

Family

ID=39732417

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070151A CU23584A1 (es) 2007-06-27 2007-06-27 Composición farmacéutica que comprende la proteína nmb1796

Country Status (5)

Country Link
US (1) US20100172931A1 (es)
EP (1) EP2168595A1 (es)
AR (1) AR067151A1 (es)
CU (1) CU23584A1 (es)
WO (1) WO2009000217A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102078569B1 (ko) 2013-12-27 2020-02-19 삼성전자 주식회사 무선 통신 시스템에서 빔 모드 운용을 위한 방법 장치

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279746B1 (en) * 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis

Also Published As

Publication number Publication date
AR067151A1 (es) 2009-09-30
WO2009000217A1 (es) 2008-12-31
EP2168595A1 (en) 2010-03-31
US20100172931A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
MX340541B (es) Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
BR112013000262A2 (pt) controle de pragas de insetos coleópteros
PT2285408T (pt) Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CO6400150A2 (es) Proteína de enlace de il-13
BR112014026744A8 (pt) anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, uso de modulação imune, uso de pelo menos uma composição de anticorpo ou fragmento de anticorpo, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, método para produzir um anticorpo ou fragmento, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada.
MX2020005235A (es) Celula humana transformada y uso de la misma.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
AR060796A1 (es) Composicion farmaceutica que comprende la proteina nmb0938
AR060797A1 (es) Composicion farmaceutica que comprende la proteina nmb0606
CU23584A1 (es) Composición farmacéutica que comprende la proteína nmb1796
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
BR112014020184A8 (pt) Preparação farmacêutica que contém anlodipina e ra-mipril
CY1115322T1 (el) Εκχυλισμα τριγωνελλας για τη θεραπεια νοσων στον ανθρωπο και τα ζωα στις οποιες εμπλεκονται μαστιγομορφα παρασιτα